今天是:

博士生导师

当前位置: 首页 -> 人才培养 -> 研究生教育 -> 导师风采 -> 博士生导师 -> 正文
顾俊莲
发布日期:2023-02-28 字号:大 中 小 点击次数:


姓名

顾俊莲

性别

出生年月

1982.05

导师聘任时间

2018

职务


职称

教授

学历

博士

学位

博士

指导研究生类型

学术学位博士研究生    学术学位硕士研究生  专业学位硕士研究生

工作单位名称(全称):

山东大学护理与康复学院

研究方向

及领域

慢性病和老年病分子机制,治疗和护理

科研项目

1.国家自然科学基金--面上项目--FGF21介导有氧运动改善衰老心肌易损性的作用及机制研究

来源:国家自然科学基金委

本人的排序:第1位(项目负责人)

2.山东省自然科学基金--面上项目--p53-TRIB3信号环路在sulforaphane改善心肌胰岛素抵抗治疗糖尿病心肌病中的作用及机制研究

来源:山东省自然科学基金委

本人的排序:第1位(项目负责人)

3.国家自然科学基金--青年基金(No.81600631 to J. Gu)成纤维细胞生长因子21通过抑制P53活性对糖尿病心肌病保护作用的研究

来源:国家自然科学基金委

本人的排序:第1位(项目负责人)

4.国家自然科学基金--面上项目锌调控P53重建前列腺癌代谢模式提高其对放化疗敏感性的机制研究

来源:国家自然科学基金委

 

科研论文

及著作

以第一作者/通讯作者发表代表性SCI文章如下: 

1.Cardiac SIRT1 ameliorates doxorubicin-induced cardiotoxicity by targeting sestrin 2. Redox biology vol. 52 (2022): 102310. doi:10.1016/j.redox.2022.102310

2.A new FGF1 variant protects against adriamycin-induced cardiotoxicity via modulating p53 activity. Redox biology vol. 49 (2022): 102219. doi:10.1016/j.redox.2021.102219

3.Metallothionein Is Downstream of Nrf2 and Partially Mediates Sulforaphane Prevention of Diabetic Cardiomyopathy. Diabetes vol. 66,2 (2017): 529-542. doi:10.2337/db15-1274

4.Metallothionein Preserves Akt2 Activity and Cardiac Function via Inhibiting TRB3 in Diabetic Hearts. Diabetes vol. 67,3 (2018): 507-517. doi:10.2337/db17-0219

5.Uncoupling the Mitogenic and Metabolic Functions of FGF1 by Tuning FGF1-FGF Receptor Dimer Stability. Cell reports vol. 20,7 (2017): 1717-1728. doi:10.1016/j.celrep.2017.06.063

6.Curtailing FGF19's mitogenicity by suppressing its receptor dimerization ability. Proc Natl Acad Sci U S A vol. 117,46 (2020): 29025-29034. doi:10.1073/pnas.2010984117

7.Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo. Eur J Cancer vol. 50,6 (2014): 1184-94. doi:10.1016/j.ejca.2013.12.027

8.Regulatory role of endogenous and exogenous fibroblast growth factor 1 in the cardiovascular system and related diseases.Pharmacological research vol. 169 (2021): 105596. doi:10.1016/j.phrs.2021.105596

9.Regulatory mechanisms of Sesn2 and its role in multi-organ diseases. Pharmacological research vol. 164 (2021): 105331. doi:10.1016/j.phrs.2020.105331

10.Molecular mechanisms of doxorubicin-induced cardiotoxicity: novel roles of sirtuin 1-mediated signaling pathways. Cellular and molecular life sciences : CMLS vol. 78,7 (2021): 3105-3125. doi:10.1007/s00018-020-03729-y

11.Murine double minute 2 siRNA and wild-type p53 gene therapy enhances sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro and in vivo. Cancer Lett vol. 343,2 (2014): 200-9. doi:10.1016/j.canlet.2013.10.011

12.Cardioprotective effects of fibroblast growth factor 21 against doxorubicin-induced toxicity via the SIRT1/LKB1/AMPK pathway. Cell Death Dis. vol. 8,8 e3018. 24 Aug. 2017, doi:10.1038/cddis.2017.410

13.Inhibition of p53 prevents diabetic cardiomyopathy by preventing early-stage apoptosis and cell senescence, reduced glycolysis, and impaired angiogenesis. Cell Death Dis. vol. 9,2 82. 23 Jan. 2018, doi:10.1038/s41419-017-0093-5

14.NRF2-Related Epigenetic Modifications in Cardiac and Vascular Complications of Diabetes Mellitus. Frontiers in endocrinology vol. 12 598005. 25 Jun. 2021, doi:10.3389/fendo.2021.598005

15.Epigenetic Regulation Associated With Sirtuin 1 in Complications of Diabetes Mellitus. Frontiers in endocrinology vol. 11 598012. 18 Jan. 2021, doi:10.3389/fendo.2020.598012

16.The Role of Fibroblast Growth Factor 21 in Diabetic Cardiovascular Complications and Related Epigenetic Mechanisms. Frontiers in endocrinology vol. 12 598008. 19 Jul. 2021, doi:10.3389/fendo.2021.598008

17.Resveratrol and FGF1 Synergistically Ameliorates Doxorubicin-Induced Cardiotoxicity via Activation of SIRT1-NRF2 Pathway. Nutrients, vol. 14, no. 19, Sept. 2022, p. 4017. Crossref, https://doi.org/10.3390/nu14194017.

18.Resveratrol Attenuates High Glucose-Induced Osteoblast Dysfunction via AKT/GSK3β/FYN-Mediated NRF2 Activation. Frontiers in pharmacology vol. 13 862618. 23 May. 2022, doi:10.3389/fphar.2022.862618

19.Co-Treatment With Resveratrol and FGF1 Protects Against Acute Liver Toxicity After Doxorubicin Treatment via the AMPK/NRF2 Pathway. Frontiers in pharmacology, vol. 13 940406. 30 Aug. 2022, doi:10.3389/fphar.2022.940406 

学术奖励、荣誉称号

(1)2012年获省级自然科学学术成果奖一等奖

(2)2014年获省级自然科学学术成果奖二等奖

(2)2018入选“山东大学齐鲁青年学者”

(3)57届SOT心血管分会 Trainee Travel Award

(4)2015度美国 APS 杰出青年研究奖(outstanding young investigator)

备注

通讯地址

山东大学护理与康复学院

邮政编码

250012

办公电话

0531-88383176

E-mail

junlian_gu@sdu.edu.cn